A practical reference on copper chelation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-15 and is reviewed periodically as new material appears.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or below | For lyophilized solid; solutions are less stable |
| Common analytical method | RP-HPLC with UV detection | For peptide purity; copper quantified separately |
| Copper quantification | ICP-MS or atomic absorption | Determines metal content and stoichiometry |
| Aqueous stability | Hours to days at room temperature | Depends on pH, buffer, and chelators |
| Color in solution | Blue | Absorption near 600 nm indicates Cu(II) coordination |
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
=== Site Master File (SMF) === A Site Master File is a document in the pharmaceutical industry which provides information about the production and control of manufacturing operations. The document is created by a manufacturer. The Site Master file contains specific and factual GMP information about the production and control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations at adjacent and nearby buildings. If only part of a pharmaceutical operation is carried out on the site, the site master file needs to describe only those operations, e.g., analysis, packaging.
=== Applied Radiation Corporation === In June 1960, High Voltage Engineering Corporation acquired Applied Radiation Corporation (ARCO) of Walnut Creek, California through a stock exchange. ARCO manufactured a line of linear accelerators with uses complementing those of HVEC's existing Van de Graaff accelerators. Applied Radiation was established as a separate subsidiary under its existing management, though its sales operations were integrated with HVEC's broader organization. The acquisition, however, would prove short-lived due to antitrust concerns. At the time, HVEC dominated the market for research accelerators, controlling an 80 percent share of orders. In April 1963, the Federal Trade Commission issued a consent decree requiring HVEC to divest itself of Applied Radiation Corporation. This forced divestiture reflected FTC concerns about concentration in the particle accelerator manufacturing industry, as both firms competed for research and industrial accelerator clients.
ago. A more correct treatment would require the use of delay differential equations. Latent period is the transition time between contagion event and disease manifestation. In cases of diseases with varying latent periods, the basic reproduction number can be calculated as the sum of the reproduction numbers for each transition time into the disease. An example of this is tuberculosis (TB). Blower and coauthors calculated from a simple model of TB the following reproduction number:
18 October — The Primary Principals Collective Bargaining Union accepts a 2.5% pay rise offer following four months of negotiations with the Ministry of Education. This will be followed by another 2.1% pay rise in 2026. 20 October: The New Zealand Government introduces two new requirements for job seeker beneficiaries who have failed a welfare obligation: engaging in three job search activities weekly and attending at least one employment-training course per month. A measles case linked to international travel is reported in Auckland. 21 October: Strong winds cause power outages, fallen trees and disrupt road and rail travel across the Wairarapa region. Lines company Powerco reports that 10,000 houses in the area have lost electricity due to fallen power lines. Strong winds and heavy rains disrupt road, rail and air travel in the Wellington Region. One person is killed by a fallen tree branch in Mount Victoria during a storm that hits Wellington. Strong winds cause four vegetation fires in the Hawke's Bay Pōrangahau area, leading to the evacuation of vie homes. Strong winds and dry conditions cause six fires in the Kaikōura District, leading to the destruction of 14 buildings and local evacuations. Three new measles cases are reported in Manawatū and Nelson. 22 October: Fire and Emergency New Zealand deploys numerous firefighters and helicopters to combat fires in the Kaikōura District and Pōrangahau. Strong winds and fires cause power outages and flight disruptions through the lower North Island and upper South Island.
Sources: en.wikipedia.org
Following Rollins' discovery in 1920 that lead aprons protected against X-rays, lead aprons with a lead thickness of 0.5 mm were introduced. Due to their weight, lead-free and lead-reduced aprons were subsequently developed. In 2005, it was recognized that in some cases the protection was significantly less than wearing lead aprons. The lead-free aprons contain tin, antimony and barium, which have the property of producing intense radiation (X-ray fluorescence radiation) when irradiated. In Germany, the Radiology Standards Committee has taken up the issue and introduced a German standard (DIN 6857-1) in 2009. The international standard IEC 61331-3:2014 was finally published in 2014. Protective aprons that do not comply with DIN 6857-1 of 2009 or the new IEC 61331-1 of 2014 may result in higher exposures. There are two classes of lead equivalency classes: 0.25 mm and 0.35 mm. The manufacturer must specify the area weight in kg/m2 at which the protective effect of a pure lead apron of 0.25 or 0.35 mm Pb is achieved. The protective effect of an apron shall be appropriate to the energy range used, up to 110 kV for low energy aprons and up to 150 kV for high energy aprons. If necessary, lead glass panels must also be used, with the front panels having a lead equivalent of 0.5-1.0 mm, depending on the application, and the side shields having a lead equivalent of 0.5-0.75 mm. Outside the useful beam, radiation exposure is primarily caused by scattered radiation from the tissue being scanned.
== Achievements == George Kenner contributed to many areas of organic chemistry. In the 1960s, George Kenner, R.A. Gregory and Hilda Tracy were involved in the seminal discovery and synthesis of the peptide hormone gastrin at the University of Liverpool. Gastrin is involved in secretion of gastric acid (HCl) in the stomach. The first chemical synthesis of a lysozyme-like enzyme of 129 amino acids using the classical approach was attempted by Kenner and his group at the University of Liverpool in the 1970s. This would have been the largest protein molecule synthesised in a laboratory using classical peptide synthesis up to that time. He carefully planned a convergent synthesis of this lysozyme analogue, containing 129 amino acid residues joined in a rigorously defined order. The efforts of Kenner and his group led to the synthesis of the 129 amino acid peptide chain in protected form. But the dream of making a wholly synthetic lysozyme enzyme was only achieved 30 years later, in 2007. This synthesis of functionally active lysozyme was achieved by a single individual, Thomas Durek, working in Steve B. Kent's group at the University of Chicago. The value of George Kenner's contributions to the methodology of peptide chemistry had profound influence on developments in many biomedicine fields. For example it led to the synthesis of antigens of defined geometry for immunological studies.
== Mechanism == Biochemical and structural analyses of aminopeptidase (APPro), methionine aminopeptidase (MetAP), and prolidase, all members of the "pita-bread" metalloenzymes, suggest that they share a common mechanism scheme. The main difference arises in the location of the carbonyl oxygen atom of the scissile peptide bond.
== Interactions == While opipramol is not a monoamine reuptake inhibitor, any irreversible MAOIs should still be discontinued at least 14 days before treatment. Opipramol can compete with other tricyclic antidepressants, beta blockers, antiarrhythmics (of class 1c), and other drugs for microsomal enzymes, which can lead to slower metabolism and higher plasma concentrations of these drugs. Co-administration of antipsychotics (e.g., haloperidol, risperidone) can increase the plasma concentration of opipramol. Barbiturates and anticonvulsants can reduce the plasma concentration of opipramol and thereby weaken its therapeutic effect.
== History == Originally discovered and developed by Eli Lilly, oritavancin was acquired by Intermune in 2001, and then by Targanta Therapeutics in 2005. In 2009, The Medicines Company acquired the development rights, completed clinical trials and submitted a new drug application to the FDA in February 2014. In August 2014, the US Food and Drug Administration approved oritavancin to treat skin infections. A marketing authorization valid throughout the European Union was granted in March 2015, for the treatment of acute bacterial skin and skin structure infections in adults.
Sources: en.wikipedia.org
=== Molecular target for epilepsy therapy === The noncompetitive AMPA receptor antagonists talampanel and perampanel have been demonstrated to have activity in the treatment of adults with partial-onset seizures, indicating that AMPA receptor antagonists represent a potential target for the treatment of epilepsy. Perampanel (trade name: Fycompa) received Marketing Authorisation Approval by the European Commission for the treatment of partial epilepsy on July 27, 2012. The drug was approved in the United States by the Food and Drug Administration (FDA) on October 22, 2012. As has been the case for most recently developed AEDs (AntiEpilectic Drugs) including pregabalin, lacosamide and ezogabine, the FDA recommended that perampanel be classified by the Drug Enforcement Administration (DEA) as a scheduled drug. It has been designated as a Schedule 3 controlled substance. Decanoic acid acts as a non-competitive AMPA receptor antagonist at therapeutically relevant concentrations, in a voltage- and subunit-dependent manner, and this is sufficient to explain its antiseizure effects. This direct inhibition of excitatory neurotransmission by decanoic acid in the brain contributes to the anticonvulsant effect of the medium-chain triglyceride ketogenic diet. Decanoic acid and the AMPA receptor antagonist drug perampanel act at separate sites on the AMPA receptor, and so it is possible that they have a cooperative effect at the AMPA receptor, suggesting that perampanel and the ketogenic diet could be synergistic.
New Zealand eGates utilise biometric technology, comparing the photo of your face in your ePassport with the photo taken of you at the gate to confirm your identity. To ensure eGate can do this, travellers must look as similar to their ePassport photos as possible and remove any glasses, scarves, or hats they were not wearing when their passport photo was taken. eGate can handle minor changes in your face, for example, if the traveller's weight or hair has changed. Customs, Biosecurity, and Immigration officials utilise information provided at eGates, including photos, to clear travellers and their items across New Zealand's border. Biometric information is kept for three months before destruction. Still, other information, including about movements across New Zealand's border, is kept indefinitely and handled in accordance with the Privacy Act 1993, or as the law authorises. This might include information being used by or shared with other law enforcement or border control authorities. Since 1 July 2019, visitors from the 60 Visa Waiver countries require a New Zealand electronic Travel Authority (NZeTA). This is an online application, and additional toolkits and requirements for airlines and travel agents can be downloaded from the New Zealand Immigration website. Singapore: The enhanced-Immigration Automated Clearance System (eIACS) is available at all checkpoints for Singapore citizens, permanent residents, foreign residents with long-term passes, APEC Business Travel Card holders, and other registered travellers.
probe Any reagent used to make a single measurement in a biochemical assay such as a gene expression experiment. Molecules which have a specific affinity for one or more other molecules may be used to probe for the presence of those other molecules in samples of unknown composition. Probes are often labelled or otherwise used as reporters to indicate whether or not a specific chemical reaction is taking place. See also hybridization probe.
The clitoris and the labia minora are both the most erogenous areas of the vulva. The labia majora are also somewhat erogenous. Local stimulation can involve the clitoris, vagina and other perineal regions. The clitoris (especially the glans) is the human female's most sensitive erogenous zone and generally the primary anatomical source of human female sexual pleasure. Sexual stimulation of the clitoris (by a number of means) can result in widespread sexual arousal and, if maintained, can result in orgasm. Stimulation to vulvar orgasm is optimally achieved by a massaging sensation, such as oral sex (cunnilingus), fingering, and tribadism (two women rubbing vulvas together). Sexual arousal results in a number of physical changes in the vulva. During arousal, the Bartholin's glands produce more vaginal lubrication. Vulval tissue is highly vascularised; arterioles dilate in response to sexual arousal and the smaller veins will compress after arousal, so that the clitoris and labia minora increase in size. Increased vasocongestion in the vagina causes it to swell, decreasing the size of the vaginal opening by about 30%. Clitoral erection takes place, which retracts the clitoral hood, causing the glans to appear. The labia majora have swollen from blood flow, and slightly separated, revealing a thick and engorged labia minora. The labia minora sometimes change considerably in color, going from pink to red in lighter skinned women who have not borne a child, or red to dark red in those who have.
== Medical uses == Isotretinoin is used primarily for persistent cystic acne. Many dermatologists also support its use for treatment of lesser degrees of acne that prove resistant to other treatments, or that produce scarring or psychological distress. Isotretinoin is not indicated for the treatment of prepubertal acne and is not recommended in children less than 12 years of age. It is also somewhat effective for hidradenitis suppurativa and some cases of severe rosacea. It can also be used to help treat harlequin ichthyosis, lamellar ichthyosis and is used in xeroderma pigmentosum cases to relieve keratoses. Isotretinoin has been used to treat the extremely rare condition fibrodysplasia ossificans progressiva. It is also used for the treatment of pediatric neuroblastoma in Japan, but data for its efficacy is not conclusive and it has not been approved in other countries. Isotretinoin therapy has furthermore proven effective against genital warts in experimental use but is rarely used for this indication as there are more effective treatments. Isotretinoin may represent an efficacious and safe alternative systemic form of therapy for recalcitrant condylomata acuminata (RCA) of the cervix. In most countries, this therapy is currently unapproved and only used if other therapies fail.
Sources: en.wikipedia.org
Peptide content is usually measured by reverse-phase high-performance liquid chromatography, while copper is measured by atomic spectroscopy. Mass spectrometry can confirm the peptide identity and detect copper adducts. Combining these methods gives a more complete picture.
pH, temperature, oxygen, light, and the presence of metal chelators all influence stability. Strong chelators can strip copper from the peptide, and reducing agents can change the copper oxidation state. Lyophilized solid stored cold and dry is generally more stable than aqueous solutions.
Purity is method-dependent because different techniques detect different impurities. A peptide purity value from HPLC does not describe copper content or the amount of free peptide. Reports should specify the analytical method and the ratio of copper to peptide.
The peptide is glycyl-L-histidyl-L-lysine, a three-amino-acid sequence commonly abbreviated GHK. It binds a single copper(II) ion under typical laboratory conditions. The free peptide and the copper complex are separate chemical species with different properties.